OBJECTIVES The goal of this study was to determine whether ticagrelor reduces high-sensitivity troponin I concentrations in patients with established coronary artery disease and high-risk coronary plaque.
C oronary plaque rupture is the most common cause of acute coronary thrombosis and myocardial infarction (1) . Patients who have an increased risk of recurrent plaque rupture events may benefit from intensification of secondary prevention therapy (2) . In this regard, the addition of a P2Y 12 receptor antagonist to low-dose aspirin reduces the risk of cardiovascular death, myocardial infarction, and stroke in patients with recent (3) or previous (4) myocardial infarction. Ticagrelor is an oral, reversible antagonist of the platelet adenosine diphosphate P2Y 12 receptor. It provides faster, more potent, and more consistent P2Y 12 inhibition than clopidogrel (5) . In the PLATO (Platelet Inhibition and Patients Outcomes) trial of 18,624 patients presenting with acute coronary syndrome, ticagrelor was superior to clopidogrel for the prevention of cardiovascular events and death (3) . Moreover, the prolonged use of dual antiplatelet therapy after myocardial infarction continues to reduce cardiovascular events, albeit at the expense of increased rates of major bleeding (4) . Thus, there is a clinical need to improve the risk stratification of patients to enable physicians to better select "vulnerable" patients who may benefit from extended duration of dual antiplatelet therapy.
A novel approach for assessing patients at high risk of coronary plaque rupture is using positron emission tomography (PET) and coronary computed tomography angiography (CTA). This technique uses the radiotracer 18 F-fluoride to identify regions of increased disease activity in coronary artery plaques.
Previous studies have shown that coronary 18 F-fluoride uptake correlates with a high-risk cardiovascular profile and identifies ruptured coronary plaques in patients with recent myocardial infarction (6, 7) . Importantly, we have previously reported an association between increased coronary 18 F-fluoride uptake and higher plasma high-sensitivity cardiac troponin I concentrations in patients with stable coronary artery disease (7) . Silent plaque rupture is common, and subclinical plaque thrombus formation is a frequent incidental post-mortem finding in patients with multivessel coronary artery disease who have died of noncardiovascular causes (8) . This result suggests that coronary 18 F-fluoride uptake may identify highrisk plaque that is associated with thrombus formation and subclinical myocardial injury from microemboli. If correct, this would potentially be modifiable with intensive dual antiplatelet therapy.
The current study assessed whether coronary 18 Ticagrelor to Reduce Myocardial Injury -2 0 The analysis of coronary 18 F-fluoride activity has been previously described (6, 7) . In brief, visual assessment for increased coronary 18 HIGH-SENSITIVITY CARDIAC TROPONIN I. Plasma high-sensitivity cardiac troponin I concentrations were measured by using the ARCHITECT STAT assay (Abbott Laboratories, Abbott Park, Illinois). The limit of detection is 1.0 ng/l with an interassay coefficient of variation <10% at 4.7 ng/l (9). The upper reference limit (99th centile) based on 4,590 samples from healthy men and women is 34 ng/l for men and 16 ng/l for women (10) . Samples were collected at baseline, 30 days, and 3, 6, 9, and 12 months. A value of 0.5 ng/l was imputed for troponin values below the limit of detection.
PLATELET FUNCTION
ANALYSIS. Platelet and monocyte activation in response to adenosine diphosphate (ADP) was determined according to flow cytometry, as previously described (11) . These analyses were performed by a single technician blinded to study allocation with the results of these investigations withheld from the study team until after trial database lock. Briefly, peripheral venous blood was obtained from all participants at the baseline and 1-month visits. Blood was drawn by clean venipuncture of a large antecubital vein using a 19-gauge needle, and care was taken to ensure a smooth blood draw without venous stasis. Blood was collected into tubes containing a direct thrombin inhibitor, D-phenylalanine-L-prolyl-L-arginine chloromethyl ketone (Cambridge Biosciences, Cambridge, United Kingdom). Tubes were gently inverted to ensure mixing of whole blood with anticoagulant.
Immunolabeling and flow cytometry were performed in whole blood to avoid centrifugation and washing steps, which can lead to artifactual platelet activation. All chemicals were obtained from BD Biosciences (Oxford, United Kingdom). Aliquots of whole
Moss et al. SAMPLE SIZE. In patients with increased coronary 18 F-fluoride uptake, we previously reported that mean AE SD troponin concentrations were more than double those in patients without increased coronary 18 F-fluoride uptake (7.9 AE 9.3 ng/l vs. 3.1 AE 1.9 ng/l; p ¼ 0.047) (7) . It was estimated that ticagrelor would reduce the troponin concentration by one-half. Fortyeight patients per treatment arm were required to achieve 80% power at 2-sided p < 0.05. After allowing for 15% dropout, we estimated that 55 patients will be required per treatment arm. Previous studies had found that 45% of patients with advanced but stable coronary artery disease exhibited increased coronary 18 F-fluoride uptake; thus, a total sample size of 250 patients was estimated to be required to identify 110 patients with increased coronary 18 Figure 2 ).
The geometric mean troponin I concentration at baseline was 3.8 (geometric SD: 2.9) ng/l in patients (12, 13) , the coronary and cerebral vascular beds differ both with respect to their underlying molecular pathophysiology and also in response to the treatment Ticagrelor to Reduce Myocardial Injury effect using ticagrelor (3, 14) . Second, our unique study design enabled high-risk patients with multivessel coronary disease and in vivo evidence of disease activity to be precisely phenotyped before randomization in a manner that can seldom be achieved in larger clinical outcome trials (3, 15) . Finally, this study is the first prospective randomized controlled trial to use high-sensitivity cardiac troponin I concentrations as a surrogate outcome measure for assessing future cardiovascular risk.
In trying to understand why P2Y 12 Ticagrelor to Reduce Myocardial Injury -2 0 1 9 : --microcalcification in regions of plaque mineralization, a key component of high-risk plaque (16) .
Hydroxyapatite, the most common form of atherosclerotic microcalcification, is extruded from apoptotic macrophages and accumulates within necrotic cores, where it may destabilize the structural integrity of the fibrous cap (17, 18) . The identification of abnormal material composition of the arterial wall has clinical relevance, as these regions may lead to atherosclerotic plaque rupture manifesting as myocardial infarction, stroke, or aneurysm rupture (7, 19, 20) . In our cohort, the frequency of 18 F-fluoride activity (>60%) in stable coronary artery disease is similar to previous estimates in patients with a high burden of coronary artery disease and previous myocardial infarction (6) . This research confirms the high prevalence of coronary 18 F-fluoride activity in stable patients with multivessel coronary artery disease who had intensification of antiplatelet therapy may be considered.
A key question is whether troponin measurements below the 99th centile reflect subclinical plaque rupture with accompanying distal microvascular embolization, as has previously been posited (21) . In this regard, some therapies directed at reducing the risk of atherosclerotic plaque rupture, such as pravastatin, both modify troponin concentrations and reduce the risk of myocardial infarction (22, 23) . In contrast, strategies that have failed to show a reduction in cardiovascular events in the context of stable coronary artery disease, such as coronary revascularization, attenuation of plaque inflammation, and Abbreviations as in Table 3 . (27, 28) .
In this study, high-sensitivity cardiac troponin I concentrations were higher in patients with 18 F-fluoride activity, although the differences were small and below the established risk stratification threshold of 5 ng/l (9, 22, 29) . It therefore seems unlikely that troponin at these concentrations reflects subclinical plaque rupture, and it is perhaps unsurprising that ticagrelor treatment did not result in an early or late reduction in troponin concentration.
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